Cybin announces unprecedented positive phase 2 interim data for cyb003 in major depressive disorder meeting primary efficacy endpoint with rapid and significant improvements in depression symptoms after single dose

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today announced phase 2 interim results for cyb003, its proprietary deuterated psilocybin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg do.
CYBN Ratings Summary
CYBN Quant Ranking